07.21.09
Mesothelioma Patients Could Improve from Clinical Trials of New Treatments
Oncologists decide what course of treatment to prescribe to a patient. There are numerous options. There exists no one size fits all treatment regimen for peritoneal mesothelioma sufferers. This is because of the relative rareness of the disease, the high mortality rate and low treatment success rate, and the few scientific studies to provide meaningful statistics.
While prospects for patients with mesothelioma have been bleak, doctors have been making progress. Customary treatments for cancer are surgery (removing the tumor and the tissue that surrounds it), radiation (killing the cancerous cells with radiation), and chemotherapy (poisoning the cancerous cells.) There are problems with all three. Patients with mesothelioma have not responded well to traditional radiation therapy. Researchers are looking for ways of aiming radiation directly at the tumor in hopes that this will result in less damage to healthy tissue.
The mesothelial tissue around the tumor is removed by surgery. This surgery is extensive and it is not clear how much the patient benefits. The usual chemotherapy cocktails effective on other cancers are not effective on mesothelioma, and different combinations of chemotherapy drugs have been tried without a lot of success. Similar to radiation, focus in research is focusing on treating the physical location of the tumor with emphasis on the pleural cavity.
The high-mortality rate for mesothelioma patients means cutting-edge techniques for cancer are tried out. These include biologic therapy such as the agent interleukin 2 and anti-angiogenesis drugs such as thalidomide. Pemetrexed (Alimta) is a new drug that has shown results in extending life.
Considered by oncologists is where the tumor is located, what stage the mesothelioma is in, and the age and health of the patient. Two exotic ways of attacking mesothelioma are gene therapy and photodynamic therapy. Patients afflicted with mesothelioma are benefitting in these clinical trials.
